Lipoxins: endogenous regulators of inflammation

Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-medi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Renal physiology 2004-02, Vol.286 (2), p.F189-F201
Main Authors: McMahon, Blaithin, Godson, Catherine
Format: Article
Language:English
Subjects:
Animals
Humans
Inflammation - immunology
Inflammation - metabolism
Lipoxins - immunology
Lipoxins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683
cites cdi_FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683
container_end_page F201
container_issue 2
container_start_page F189
container_title American journal of physiology. Renal physiology
container_volume 286
creator McMahon, Blaithin
Godson, Catherine
description Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-mediated injury, stimulation of macrophage clearance of apoptotic neutrophils, repression of proinflammatory cytokine production, modulation of cytokine-stimulated metalloproteinase activity, and inhibition of cell proliferation and migration. An overview of recent advances in LX physiology is provided, with particular emphasis on the cellular and molecular processes involved. These data coupled with in vivo models of inflammatory diseases suggest that LX bioactions may be amenable to pharmacological mimicry for therapeutic gain.
doi_str_mv 10.1152/ajprenal.00224.2003
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80079532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80079532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683</originalsourceid><addsrcrecordid>eNpFkE9LxDAQxYMo7rr6CQTpyVt3Z9KkabzJ4j9Y8KLgLSRtunRpk5q0oN_errviaYaZ9x6PHyHXCEtETld61wfrdLsEoJQtKUB2QubTh6bI8vx02mWGacHFx4xcxLgDAESK52SGTIAA4HOy2jS9_2pcvEusq_zWOj_GJNjt2OrBh5j4Omlc3equ00Pj3SU5q3Ub7dVxLsj748Pb-jndvD69rO83acm4GFJTlciQGgsFNyWVlaDCcmk0cFEWEpBLViGdzjVoJg1UFGUutMG6zkxeZAtye8jtg_8cbRxU18TStq12dmqoCgAheUYnYXYQlsHHGGyt-tB0OnwrBLXnpP44qV9Oas9pct0c40fT2erfcwST_QB2p2VR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80079532</pqid></control><display><type>article</type><title>Lipoxins: endogenous regulators of inflammation</title><source>American Physiological Society Free</source><creator>McMahon, Blaithin ; Godson, Catherine</creator><creatorcontrib>McMahon, Blaithin ; Godson, Catherine</creatorcontrib><description>Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-mediated injury, stimulation of macrophage clearance of apoptotic neutrophils, repression of proinflammatory cytokine production, modulation of cytokine-stimulated metalloproteinase activity, and inhibition of cell proliferation and migration. An overview of recent advances in LX physiology is provided, with particular emphasis on the cellular and molecular processes involved. These data coupled with in vivo models of inflammatory diseases suggest that LX bioactions may be amenable to pharmacological mimicry for therapeutic gain.</description><identifier>ISSN: 1931-857X</identifier><identifier>EISSN: 1522-1466</identifier><identifier>DOI: 10.1152/ajprenal.00224.2003</identifier><identifier>PMID: 14707005</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Humans ; Inflammation - immunology ; Inflammation - metabolism ; Lipoxins - immunology ; Lipoxins - metabolism</subject><ispartof>American journal of physiology. Renal physiology, 2004-02, Vol.286 (2), p.F189-F201</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683</citedby><cites>FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14707005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McMahon, Blaithin</creatorcontrib><creatorcontrib>Godson, Catherine</creatorcontrib><title>Lipoxins: endogenous regulators of inflammation</title><title>American journal of physiology. Renal physiology</title><addtitle>Am J Physiol Renal Physiol</addtitle><description>Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-mediated injury, stimulation of macrophage clearance of apoptotic neutrophils, repression of proinflammatory cytokine production, modulation of cytokine-stimulated metalloproteinase activity, and inhibition of cell proliferation and migration. An overview of recent advances in LX physiology is provided, with particular emphasis on the cellular and molecular processes involved. These data coupled with in vivo models of inflammatory diseases suggest that LX bioactions may be amenable to pharmacological mimicry for therapeutic gain.</description><subject>Animals</subject><subject>Humans</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Lipoxins - immunology</subject><subject>Lipoxins - metabolism</subject><issn>1931-857X</issn><issn>1522-1466</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkE9LxDAQxYMo7rr6CQTpyVt3Z9KkabzJ4j9Y8KLgLSRtunRpk5q0oN_errviaYaZ9x6PHyHXCEtETld61wfrdLsEoJQtKUB2QubTh6bI8vx02mWGacHFx4xcxLgDAESK52SGTIAA4HOy2jS9_2pcvEusq_zWOj_GJNjt2OrBh5j4Omlc3equ00Pj3SU5q3Ub7dVxLsj748Pb-jndvD69rO83acm4GFJTlciQGgsFNyWVlaDCcmk0cFEWEpBLViGdzjVoJg1UFGUutMG6zkxeZAtye8jtg_8cbRxU18TStq12dmqoCgAheUYnYXYQlsHHGGyt-tB0OnwrBLXnpP44qV9Oas9pct0c40fT2erfcwST_QB2p2VR</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>McMahon, Blaithin</creator><creator>Godson, Catherine</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040201</creationdate><title>Lipoxins: endogenous regulators of inflammation</title><author>McMahon, Blaithin ; Godson, Catherine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Lipoxins - immunology</topic><topic>Lipoxins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McMahon, Blaithin</creatorcontrib><creatorcontrib>Godson, Catherine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of physiology. Renal physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McMahon, Blaithin</au><au>Godson, Catherine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipoxins: endogenous regulators of inflammation</atitle><jtitle>American journal of physiology. Renal physiology</jtitle><addtitle>Am J Physiol Renal Physiol</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>286</volume><issue>2</issue><spage>F189</spage><epage>F201</epage><pages>F189-F201</pages><issn>1931-857X</issn><eissn>1522-1466</eissn><abstract>Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-mediated injury, stimulation of macrophage clearance of apoptotic neutrophils, repression of proinflammatory cytokine production, modulation of cytokine-stimulated metalloproteinase activity, and inhibition of cell proliferation and migration. An overview of recent advances in LX physiology is provided, with particular emphasis on the cellular and molecular processes involved. These data coupled with in vivo models of inflammatory diseases suggest that LX bioactions may be amenable to pharmacological mimicry for therapeutic gain.</abstract><cop>United States</cop><pmid>14707005</pmid><doi>10.1152/ajprenal.00224.2003</doi></addata></record>
fulltext fulltext
identifier ISSN: 1931-857X
ispartof American journal of physiology. Renal physiology, 2004-02, Vol.286 (2), p.F189-F201
issn 1931-857X
1522-1466
language eng
recordid cdi_proquest_miscellaneous_80079532
source American Physiological Society Free
subjects Animals
Humans
Inflammation - immunology
Inflammation - metabolism
Lipoxins - immunology
Lipoxins - metabolism
title Lipoxins: endogenous regulators of inflammation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A19%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipoxins:%20endogenous%20regulators%20of%20inflammation&rft.jtitle=American%20journal%20of%20physiology.%20Renal%20physiology&rft.au=McMahon,%20Blaithin&rft.date=2004-02-01&rft.volume=286&rft.issue=2&rft.spage=F189&rft.epage=F201&rft.pages=F189-F201&rft.issn=1931-857X&rft.eissn=1522-1466&rft_id=info:doi/10.1152/ajprenal.00224.2003&rft_dat=%3Cproquest_cross%3E80079532%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c457t-bdc1412be085bc29d727e59ba057c8901594d12d72f0a49b0d21967ab1ff3b683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=80079532&rft_id=info:pmid/14707005&rfr_iscdi=true